The therapy of pulmonary fibrosis in paracoccidioidomycosis: what are the new experimental approaches?

Á González - Journal of Fungi, 2020 - mdpi.com
Pulmonary fibrosis (PF) is considered the most important sequela developed in patients
suffering from the chronic form of paracoccidioidomycosis (PCM), which leads to the loss of …

Mesoporous SBA-16 silica nanoparticles as a potential vaccine adjuvant against Paracoccidioides brasiliensis

DCF Soares, LM Soares, AM de Goes, EM Melo… - Microporous and …, 2020 - Elsevier
Nanostructured materials including mesoporous silica nanoparticles (MSNs) have attracted
attention due to their recently discovered capability to increase the immune responses …

Immunization with recombinant Pb27 protein reduces the levels of pulmonary fibrosis caused by the inflammatory response against Paracoccidioides brasiliensis

EA Morais, EMN Martins, JN Boelone, DA Gomes… - Mycopathologia, 2015 - Springer
Paracoccidioidomycosis (PCM) is a systemic mycosis in which the host response to the
infectious agent typically consists of a chronic granulomatous inflammatory process. This …

[HTML][HTML] TLR 9 involvement in early protection induced by immunization with rPb27 against Paracoccidioidomycosis

EA Morais, DF Chame, EM Melo… - Microbes and …, 2016 - Elsevier
Paracoccidioidomycosis is caused by fungi of the Paracoccidioides genus and constitutes
the most prevalent deep mycosis in Latin America. Toll-like receptors promote immune …

[PDF][PDF] Efficacy of Chitosan as Vaccine Adjuvant Against Paracoccidioidomycosis in Mice

EA Morais, JA de Carvalho Oliveira, EM Melo… - J Immunol Infect …, 2018 - researchgate.net
Paracoccidioidomycosis (PCM) is a systemic disease caused by thermo-dimorphic fungi of
Paracoccidioides genus that is endemic in several Latin American countries. The treatment …